PLAINSBORO, N.J. – Novo Nordisk announced on Wednesday it has transitioned from blister packs to 30-count recyclable bottles for Rybelsus (semaglutide) tablets 3 mg, 7 mg, or 14 mg. Moving to a single, fully recyclable 30-count bottle minimizes waste and supports Novo Nordisk’s “Circular for Zero” initiative, aiming to reduce the company’s environmental impact. This transition
WOONSOCKET, R.I. — CVS Health and Novo Nordisk Inc. announced today that the two companies are piloting a new, personalized nutrition coaching program to support people struggling with obesity, after their treatment plan has been determined by a licensed provider. More than 40 percent of the U.S. population suffers from obesity, a chronic disease that
ABBOTT PARK, Ill. —Abbott and Novo Nordisk announced Wednesday a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly into the digital health tools compatible with the FreeStyle Libre system (FreeStyle LibreLinkii mobile app and LibreViewiii cloud-based system). The partnership reflects both companies′ commitment to make diabetes
WEST DES MOINES, Iowa — In honor of National Diabetes Awareness Month, Hy-Vee, Inc. will provide free Hemoglobin A1C screenings throughout its eight-state region during the month of November. The free Hemoglobin A1C screenings will be offered on a first-come, first-served basis at the Hy-Vee Healthy You Mobiles in 168 Hy-Vee store parking lots. Hy-Vee
PLAINSBORO, N.J. — Novo Nordisk has released two new diabetes medications, Ozempic (semaglutide injection 0.5 mg and 1 mg) and Fiasp (insulin aspart injection 100 units/ml), to U.S. pharmacies. Both medications gained Food and Drug Administration approval in 2017 and mark the latest advancements to Novo Nordisk’s diabetes portfolio, the company said Monday. Ozempic is a
PLAINSBORO, N.J. — Novo Nordisk this week gained Food and Drug Administration approval for Ozempic (semaglutide injection), a medication for type 2 diabetes. Also this week, Novo Nordisk and pharmacy benefit manager Prime Therapeutics said they signed a value-based contract for Victoza (liraglutide injection), another type 2 diabetes medication. A glucagon-like peptide (GLP-1) receptor agonist,
PLAINSBORO, N.J. — Novo Nordisk has launched Xultophy 100/3.6, a combination therapy insulin pen, at pharmacies nationwide. Xultophy 100/3.6 combines the long-acting basal insulin Tresiba (insulin degludec U-100) with the No. 1-prescribed glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy Victoza (liraglutide 3.6 mg/ml) in a once-daily injection, Novo Nordisk said. The prefilled pen is indicated as
WOONSOCKET, R.I. — CVS Health last month announced the launch of Reduced Rx, a prescription savings program offering discounts on certain medications directly to patients through the company’s pharmacy benefits manager, CVS Caremark. The announcement came a day after the company reported that prescription growth for CVS Caremark clients slowed in 2016 to its lowest
WOONSOCKET, R.I. — CVS Health plans to serve up discounts on certain medications via a new prescription drug savings program called Reduced Rx. CVS said Thursday that Reduced Rx is designed to help patients with high out-of-pocket costs afford vital medications. The discounts will be offered directly to patients through CVS Caremark, the company’s pharmacy benefit
BAGSVÆRD, Denmark — Lars Rebien Sørensen, president and chief executive officer of Novo Nordisk A/S, is retiring from the company and will be succeeded by Lars Fruergaard Jørgensen. Plans call for Jørgensen, executive vice president and head of corporate development, to take the CEO reins on Jan. 1, Novo Nordisk said Thursday. Sørensen is slated to
CLAYTON, N.C. — Novo Nordisk Inc. has broken ground on a new $1.8 billion diabetes medicine production facility in Clayton, N.C. The 833,000-square-f00t Clayton facility will make active pharmaceutical ingredients (API) for a range of Novo Nordisk’s current and future GLP-1 and insulin medicines. Plans call for the facility to become fully operational in 2020
PLAINSBORO, N.J. — Novo Nordisk Inc. has rolled out Tresiba, a once-daily, long-acting basal insulin, to U.S. pharmacies. Novo Nordisk said Tuesday that Tresiba (insulin degludec injection), provides a more flexible option for adults with diabetes who require insulin therapy, who often must plan their schedules to accommodate the need to take insulin at the
BAGSVAERD, Denmark — Novo Nordisk plans to acquire Calibrium LLC and MB2 LLC, two privately held biopharmaceutical research companies based in Carmel, Ind. The Danish pharmaceutical company said Thursday that the acquisition will expand its portfolio of projects and intellectual property rights in the diabetes and obesity segments and help expand Novo Nordisk’s research presence
DEERFIELD, Ill. — A new white paper from Walgreens finds that its Balance Rewards for healthy choices (BRhc) loyalty program is encouraging healthier behaviors by members, including weight loss and improved medication adherence by those with hypertension and/or diabetes. The drug chain said Thursday that the white paper data, from a series of related Walgreens
